SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

Community sentiment remains deeply polarized as investors debate whether the asset represents a viable political statement or a speculative scam. Discussion is dominated by concerns over its significant decline from all-time highs, with many users warning of potential delistings while others continue to speculate on price volatility.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is trending as investors debate the impact of broader market volatility, with community members actively discussing a potential breakout versus continued downside. Discussions center on the asset's long-term utility and historical halving cycles, contrasted with bearish sentiment surrounding its recent performance relative to other major cryptocurrencies.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is gaining traction as traders speculate on potential ecosystem growth and data-driven infrastructure developments, despite ongoing community debate regarding long-term tokenomics and project leadership. The asset remains a focal point for investors tracking Japan's evolving regulatory landscape and its potential impact on the broader IoT and blockchain sector.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is trending as investors debate the impact of potential regulatory clarity and institutional adoption versus concerns over long-term token supply and market performance. The community remains deeply divided between long-term holders accumulating on dips and skeptics who criticize the project's price action and dilution model.

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

Tango Therapeutics Inc

Tango Therapeutics is trending as investors react to a significant clinical data update for its cancer drug combination, sparking high volatility, increased trading volume, and intense community debate over potential short-squeeze dynamics and future clinical milestones.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

REalloys is attracting significant attention as investors monitor its push to build a domestic, non-Chinese rare earth supply chain ahead of critical upcoming defense procurement deadlines. Community members are actively discussing the company's recent Russell 3000 index inclusion, analyst price targets, and potential for institutional inflows as the market prioritizes strategic independence in critical minerals.

TOSHI

TOSHI is trending as the community rallies around rumors of a pivot from a meme coin to a utility-focused AI platform featuring a buyback-and-lock mechanism. Investors are debating current entry points as the stock maintains a tight trading range while they anticipate major ecosystem partnerships and potential retail adoption catalysts.

Lemonade, Inc. is a holding company, which engages in the provision of insurance services. The firm's products include renters and homeowners insurance, and pet insurance. It offers insurance coverage under the homeowners multi-peril, inland marine, and general liability lines of business. The company was founded by Daniel Asher Schreiber and Shai Wininger on June 17, 2015 and is headquartered in New York, NY.

Lemonade Inc

Lemonade is seeing significant market activity as investors react to a bullish Morgan Stanley upgrade, which highlights the company's autonomous insurance partnership with Tesla as a key growth catalyst. While community sentiment remains divided between long-term confidence in its AI-first model and concerns over high volatility, traders are actively monitoring the stock's consolidation patterns ahead of upcoming earnings.

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.

Absci Corp

Absci Corp is gaining momentum as investors react to a strategic collaboration with Oracle and AMD aimed at accelerating AI-driven drug discovery, alongside growing excitement about its internal pipeline, particularly the ABS-201 alopecia program. The community is actively debating the stock's potential for a short squeeze given its high short interest, while balancing optimism over AI-biotech synergy against concerns regarding clinical execution and previous volatility.

iShares Trust - iShares Biotechnology ETF

iShares Biotechnology ETF

The iShares Biotechnology ETF is capturing attention as the sector experiences a surge in M&A activity and positive data readouts, fueling investor optimism for a sustained bull run. Community discussion remains heavily focused on potential buyout targets among commercial-stage biotech firms and the impact of breakthrough trial results on valuation multiples.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

A Congress Member Sold Up To $65K In Bristol-Myers Squibb Stock: Here's What You Need To Know

Mariska Hargitay Partners with Bristol Myers Squibb for Investigating Myeloma Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

Bristol Myers Squibb (NYSE: BMY) today announced the launch of Investigating Myeloma, a multiple myeloma awareness campaign, in partnership with award-winning actor, director, producer and advocate Mariska Hargitay. This campaign spotlights the importance of ongoing scientific investigation in...

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PDL1/VEGFA Bispecific Immunomodulator to Treat Kidney Cancer

Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with...

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced that SystImmunes parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), reported positive results from prespecified interim analyses of two Phase 3 studies...

Full Transcript: Bristol-Myers Squibb Q1 2026 Earnings Call

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibbs Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Camzyos (mavacamten) as a potential treatment for adolescents (ages 12 years to &lt;18 years) with symptomatic obstructive hypertrophic cardiomyopathy...

Bristol Myers Squibb Announces Opdivo (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma

Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with doxorubicin, vinblastine and dacarbazine (AVD) for the treatment of adult and adolescent patients 12 years of age and older with previously untreated Stage III or...

Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma

Bristol Myers Squibb (NYSE: BMY) today announced positive late-breaking results from the Phase 3 SUCCESSOR-2 trial (NCT05552976) of CELMoD (cereblon E3 ligase modulation) mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) versus carfilzomib and dexamethasone alone (Kd) in...

Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026. The company will take part in a fireside chat beginning at 2:00 p.m. ET. Investors and the general public are invited to listen...

Is Bristol-Myers Squibb (BMY) One of the Best Dividend Stocks to Invest in According to Hedge Funds?

Is Bristol-Myers Squibb (BMY) One of the Best Dividend Stocks to Invest in According to Hedge Funds...

CELGCelgene Corporation

Feed

News

Sentiment

Fundamentals

Info

Latest CELG News